RxDoctor Payments Data

James Brown, MD

Obstetrics & Gynecology · Lake Charles, LANPI 1730159807

Payments from drug & device makers

$6,145in general payments, 2019–2025

Across 220 payments — averaging $27.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coloplast$2K
  • AbbVie$893
  • Pfizer$449
  • AMAG Pharmaceuticals, Inc.$223
  • Takeda Pharmaceuticals U.S.A., Inc.$199
  • Astellas Pharma US Inc$172
  • plus $2K from 31 others

What the payments were for

  • Travel & lodging$1,69228%
  • Food & beverage$4,35571%
  • Education$982%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,145 in reported general payments places this provider in the 85th percentile of 608 obstetrics & gynecology providers in Louisiana.

See all obstetrics & gynecology providers in Louisiana

Medicare billing

Part B allowed, 2024
$21,594
Medicare patients
129
Services billed
234

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron22$11,416
PremarinEstrogens, Conjugated23$5,968
Estradiol170$4,582
ValacyclovirValacyclovir Hcl19$1,491
DottiEstradiol13$1,294
ProgesteroneProgesterone, Micronized13$614
Bupropion XlBupropion Hcl17$552
Estradiol (Once Weekly)Estradiol11$456
Escitalopram Oxalate25$338
Fluoxetine Hcl17$303
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst22$247
Levothyroxine Sodium15$210
Sertraline Hcl16$183
Zolpidem Tartrate34$124
Fluconazole32$119

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$172$11,41622 claims
PfizerPremarin$449$5,96823 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 608 obstetrics & gynecology providers in Louisiana.

Other obstetrics & gynecology in Lake Charles

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →